Physician profile
Xiao Su
NPI 1659505774
$16,448.77
in general payments reported to CMS, 2019-2025
43 companies · $6,092 in 2025
The $6,092 reported for 2025 was more than what 76% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $190 · 2021: $355 · 2022: $5,169 · 2023: $1,922 · 2024: $1,888 · 2025: $6,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,950 · Consulting Fee: $2,710 · Education: $826 · Travel and Lodging: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,949.84 |
| Consulting Fee | $2,710.00 |
| Education | $826.01 |
| Travel and Lodging | $415.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $4,565.05 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,924.25 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,918.93 | 2019-2025 | Tagrisso, Datroway, Calquence |
| E.R. Squibb & Sons, L.L.C. | $1,131.58 | 2019-2025 | Opdivo, Reblozyl, Augtyro |
| Janssen Biotech, INC. | $683.28 | 2023-2025 | Rybrevant, Carvykti, Tecvayli |
| Daiichi Sankyo INC. | $548.79 | 2020-2025 | Enhertu, Injectafer, Vanflyta |
| Regeneron Healthcare Solutions, INC. | $513.94 | 2022-2025 | Libtayo |
| Astellas Pharma US INC | $490.70 | 2023-2025 | Xtandi, Vyloy, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $486.12 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| Amgen INC. | $400.86 | 2019-2023 | Nplate, Xgeva |
| Merck Sharp & Dohme LLC | $338.92 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Beigene USA, INC. | $311.04 | 2023-2024 | Brukinsa |
| Incyte Corporation | $263.35 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Seagen INC. | $224.23 | 2019-2025 | |
| Abbvie INC. | $210.13 | 2022-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $196.72 | 2019-2025 | Reblozyl, Pomalyst |
| Ipsen Biopharmaceuticals, INC | $185.43 | 2019-2025 | Onivyde, Tazverik |
| Pfizer INC. | $175.99 | 2024-2025 | |
| Gilead Sciences, INC. | $172.69 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $169.25 | 2019-2025 | Polivy, Lunsumio, Phesgo |
| Exelixis INC. | $164.11 | 2019-2024 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $156.84 | 2019-2025 | Ultomiris |
| Sobi, INC | $132.52 | 2025 | Vonjo |
| Janssen Pharmaceuticals, INC | $125.74 | 2023 | Xarelto |
| Rigel Pharmaceuticals, INC. | $125.01 | 2022 | |
| Genzyme Corporation | $116.55 | 2019-2025 | |
| Icotec Medical INC. | $109.09 | 2023 | Icotec Blackarmor Spine System |
| Emd Serono, INC. | $92.26 | 2023-2025 | Bavencio |
| Tersera Therapeutics LLC | $72.43 | 2025 | Zoladex |
| Genmab U.S., INC. | $49.24 | 2025 | Tivdak, Epkinly |
| Aveo Pharmaceuticals, INC. | $47.80 | 2025 | |
| Novartis Pharmaceuticals Corporation | $44.45 | 2024-2025 | |
| Array Biopharma INC | $42.91 | 2025 | Braftovi, Mektovi, Tukysa |
| Puma Biotechnology, INC. | $41.82 | 2024-2025 | |
| Lilly USA, LLC | $40.30 | 2019-2025 | Verzenio, Jaypirca |
| Iovance Biotherapeutics, INC. | $35.49 | 2025 | Amtagvi |
| Jazz Pharmaceuticals INC. | $29.51 | 2025 | |
| Pharmacosmos Therapeutics INC. | $27.69 | 2024 | Monoferric |
| Glaxosmithkline, LLC. | $18.76 | 2025 | Jemperli |
| Servier Pharmaceuticals LLC | $18.59 | 2024 | |
| Eisai INC. | $16.09 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.52 | 2019 | |
| Springworks Therapeutics, INC. | $14.80 | 2024 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiao Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.